Immunotherapy of Established (Pre)malignant Disease by Synthetic Long Peptide Vaccines

Nat Rev Cancer. 2008 May;8(5):351-60. doi: 10.1038/nrc2373.

Abstract

This Review deals with recent progress in the immunotherapy of established (pre)malignant disease of viral or non-viral origin by synthetic vaccines capable of inducing robust T-cell responses. The most attractive vaccine compounds are synthetic long peptides (SLP) corresponding to the sequence of tumour viral antigens or tumour-associated non-viral antigens. Crucial to induction of therapeutic T-cell immunity is the capacity of SLP to deliver specific cargo to professional antigen-presenting cells (dendritic cells (DC)). Proper DC activation then induces the therapeutic CD4+ and CD8+ T-cell responses that are associated with regression of established (pre)malignant lesions, including those induced by high-risk human papilloma virus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use
  • Dendritic Cells / immunology
  • Humans
  • Immunotherapy, Active*
  • Mice
  • Peptides / immunology*
  • Precancerous Conditions / drug therapy*
  • Precancerous Conditions / etiology
  • Precancerous Conditions / virology
  • Rabbits
  • Vaccines, Subunit / immunology
  • Vaccines, Subunit / therapeutic use

Substances

  • Cancer Vaccines
  • Peptides
  • Vaccines, Subunit